Skip to main content
Fig. 3 | Journal of Hematology & Oncology

Fig. 3

From: Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma

Fig. 3

Construction of BCMA-specific CAR and protocol of anti-BCMA CAR-T cell infusions following chemotherapy. a Schematic diagram of anti-BCMA CAR vector. SP signal peptide, VH variable H chain, L linker, VL variable L chain. A protocol of CAR-T infusion in combination with chemotherapy. Chemotherapy included fludarabine and cyclophosphamide. CAR-T cells were infused at a total dose of 1 × 107/kg for 3 days (b a patient of POEMS syndrome) and 5.6 × 106/kg for 2 days (c a patient of multiple myeloma)

Back to article page